by Mark Chiang

马克·蒋

Share To

分享到

Vertex Pharmaceuticals has encountered setbacks in its efforts to expand the use of its pain medication, Journavx, and advance a successor drug. The company announced that gaining regulatory approval to use Journavx for chronic pain will require additional clinical testing. Simultaneously, a follow-up drug candidate, VX-993, failed to meet expectations in a Phase 2 clinical trial.

Vertex制药公司在扩大其止痛药Journavx的使用范围并推进后续药物的过程中遭遇了挫折。该公司宣布，获得将Journavx用于慢性疼痛的监管批准需要进行额外的临床试验。同时，后续药物候选品VX-993在二期临床试验中未能达到预期效果。

These developments led to a significant drop in Vertex’s market value..

这些发展导致 Vertex 的市值显著下降。

The company disclosed the updates during an investor briefing, where it explained that further studies are necessary to demonstrate Journavx’s efficacy and safety for chronic pain treatment. This requirement delays the timeline for potential approval in this broader indication. Meanwhile, VX-993, which was being developed as a next-generation treatment option, did not achieve its desired outcomes in mid-stage trials.

公司在投资者简报中披露了这些更新，并解释称，需要进一步研究以证明Journavx在慢性疼痛治疗中的有效性和安全性。这一要求推迟了该药物在更广泛适应症中获得潜在批准的时间表。同时，作为下一代治疗选择正在开发的VX-993在中期试验中未能达到预期结果。

The combination of these challenges has raised concerns about Vertex’s progress in addressing unmet needs in pain management and impacted investor confidence..

这些挑战的结合引发了人们对Vertex在解决疼痛管理未满足需求方面的进展的担忧，并影响了投资者的信心。

Newsflash | Powered by GeneOnline AI

新闻快讯 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

来源：GO-AI-ne1

Date: August 5, 2025

日期：2025年8月5日

Related posts:

相关文章：

Researchers Identify Skin Neutrophils That Generate Protective Extracellular Matrix

研究人员发现生成保护性细胞外基质的皮肤中性粒细胞

Camzyos Trial Fails in Specific HCM Subtype, Raising Questions About Myosin Inhibitor Class

Camzyos试验在特定HCM亚型中失败，引发对肌球蛋白抑制剂类别的质疑

Background Color Hex Codes Revealed for Five Tabs in Pharmaceutical Content Platform

药品内容平台中五个标签的背景颜色十六进制代码揭晓

Hepatitis C Virus Found in Cells Lining the Human Brain Suggesting Link to Psychiatric Disorders

丙型肝炎病毒在人类大脑内壁细胞中发现，提示其与精神疾病存在关联

©www.geneonline.com All rights reserved. Collaborate with us:

©www.geneonline.com 版权所有。与我们合作：

[email protected]

[email protected]

Author

作者

Mark Chiang

蒋志光

Related Post

相关文章

News Flash

新闻快讯

Wet Granulation Process Used in Pharmaceutical Manufacturing to Improve Powder Compressibility and Ensure Precise Dosage

湿法制粒工艺用于制药生产中以提高粉末的可压性和确保精确的剂量。

2025-08-05

2025年8月5日